Mirati Therapeutics (NASDAQ: MRTX) is a San Diego-based clinical-stage biotechnology company dedicated to advancing novel therapeutics that extend the lives of patients by directly addressing the genetic and immunological drivers of cancer. Mirati's lead drug candidate, sitravatinib, is designed to selectively target a spectrum of tyrosine kinases implicated in both tumor growth and the suppression of immune responses to tumors. Sitravatinib has demonstrated durable responses in lung cancer patients whose cancer has progressed despite treatment with checkpoint inhibitors - an area of significant unmet medical need. Sitravatinib is being evaluated in multiple clinical trials to treat patients who are refractory to prior immune checkpoint inhibitor therapy, including a potentially registration-enabling Phase 3 trial of sitravatinib in combination with a checkpoint inhibitor in non-small cell lung cancer (NSCLC) that is currently enrolling patients. Source
No articles found.
Calithera is a clinical-stage biopharmaceutical company pioneering the discovery a...
Calithera is a clinical-stage biopharmaceutical...
Rockwell Medical (NASDAQ: RMTI) is a fully-integrated biopharmaceutical company ta...
Rockwell Medical (NASDAQ: RMTI) is a fully-inte...
Inovio is bringing IMMUNO-INGENUITY⢠to life and is reshaping the future of trea...
Inovio is bringing IMMUNO-INGENUITY⢠to life ...
Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into ...
Sangamo Therapeutics, Inc. is focused on transl...
Fisher Wallace manufactures and markets wearable medical devices for the treatment...
Fisher Wallace manufactures and markets wearabl...
CHF Solutions is focused on improving the quality of life for patients suffering f...
CHF Solutions is focused on improving the quali...
Corcept is a pharmaceutical company engaged in the discovery, development and comm...
Corcept is a pharmaceutical company engaged in ...
Join the National Investor Network and get the latest information with your interests in mind.